Ozmosi | [225Ac]Ac-ETN029 Drug Profile
Drug Profile
Using advanced filters...
Advanced Search [+]

[225Ac]Ac-ETN029

Alternative Names: [225Ac]Ac-ETN029, 225Ac-ETN029, 225AcETN029
Clinical Status: Inactive
Latest Update: 2026-03-24
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Imaging Agent

Novel Mechanism: No

Modality: Radiopharmaceutical

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Novartis
Company Location: Europe
Company Founding Year: 1996
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Recent News Events

Date

Type

Title